This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
Cancer				
Brain cancer	Low-density lipoprotein receptor-related protein 1 α -2-macroglobulin receptor (LRP1; CD91)	<p>A study in mice and in cell culture suggests that angiopep-2-conjugated doxorubicin and etoposide could help treat brain cancer. The angiopep-2 peptide transports compounds across the blood brain barrier (BBB) via an LRP1-mediated mechanism. In a panel of three human cancer cell lines, angiopep-2-conjugated drugs showed cytotoxicity with nanomolar IC_{50} values. In a mouse model of human glioma, angiopep-2-conjugated drugs had higher distribution in the brain and brain tumor than did unconjugated drugs. Next steps include toxicology studies.</p> <p>ANG1005, an angiopep-2 vector conjugated to three paclitaxel molecules from AngioChem Inc., is in Phase I/II testing to treat brain cancer.</p> <p>AngioChem also is developing ANG1007 and ANG1009, which are angiopep-2 vectors conjugated to three doxorubicin or etoposide molecules, respectively. Those compounds are in preclinical development for cancer.</p> <p>SciBX 3(12); doi:10.1038/scibx.2010.368 Published online March 25, 2010</p>	Patent applications filed covering composition of matter and use in treating diseases such as cancer; ANG1007 and ANG1009 available for licensing from AngioChem	<p>Ché, C. <i>et al. J. Med. Chem.</i>; published online March 8, 2010; doi:10.1021/jm9016637</p> <p>Contact: Michel Demeule, AngioChem Inc., Montreal, Quebec, Canada e-mail: mdemeule@angiochem.com</p>